Department of Breast Surgery, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241286872. doi: 10.1177/15330338241286872.
To investigate the differences in serum tryptophan, lysine, and phenylalanine levels in breast cancer patients, the correlation between the three amino acids with the chemotherapy regimen, and their significance in the clinical diagnosis and treatment of breast cancer.Clinical data were collected from the Department of Breast Surgery at Yunnan Cancer Hospital, encompassing 216 cases from July to December 2020, including 91 healthy individuals, 38 with benign tumors, and 87 with cancer. Amino acid levels were measured using liquid chromatography-tandem mass spectrometry. Statistical analyses, such as the Kruskal-Wallis H-test and Wilcoxon test, were conducted to compare the levels of these amino acids across the healthy group, benign tumor group, and breast cancer group. The χ2 test and Fisher's exact probability method were employed to assess the relationship between amino acid levels and breast cancer stage, grade, and chemotherapy regimen.The results indicated that there were significant differences in serum lysine (H = 36.13, < .001) and phenylalanine (H = 34.03, < .001) levels among the three groups. However, tryptophan levels did not show statistically significant variances. Specifically, lysine and phenylalanine levels were significantly different when comparing the healthy group with the breast cancer group and the benign tumor group with the breast cancer group. These differences were not significant when comparing the healthy group with the benign tumor group. Furthermore, there were no statistically significant distinctions observed in lysine (F = 0.836, > .05) and phenylalanine (F = 1.466, > .05) levels across different conventional chemotherapy regimens among the breast cancer cases studied.Serum lysine and phenylalanine levels might serve as potential biomarkers for breast cancer, and the choice of chemotherapy regimen is unlikely to impact significant changes in these amino acid levels.
为了研究乳腺癌患者血清色氨酸、赖氨酸和苯丙氨酸水平的差异，以及这三种氨基酸与化疗方案的相关性，及其在乳腺癌临床诊断和治疗中的意义。本研究收集了 2020 年 7 月至 12 月云南省肿瘤医院乳腺外科的临床资料，共 216 例，其中健康对照组 91 例，良性肿瘤组 38 例，乳腺癌组 87 例。采用液相色谱-串联质谱法测定氨基酸水平。采用 Kruskal-Wallis H 检验和 Wilcoxon 检验比较健康组、良性肿瘤组和乳腺癌组的氨基酸水平。采用 χ2 检验和 Fisher 确切概率法分析氨基酸水平与乳腺癌分期、分级和化疗方案的关系。结果表明，三组间血清赖氨酸（H=36.13，<0.001）和苯丙氨酸（H=34.03，<0.001）水平差异有统计学意义。而色氨酸水平差异无统计学意义。具体来说，健康组与乳腺癌组、良性肿瘤组与乳腺癌组比较，赖氨酸和苯丙氨酸水平差异有统计学意义；健康组与良性肿瘤组比较，赖氨酸和苯丙氨酸水平差异无统计学意义。此外，研究的乳腺癌病例中，不同常规化疗方案之间赖氨酸（F=0.836，>0.05）和苯丙氨酸（F=1.466，>0.05）水平无统计学差异。血清赖氨酸和苯丙氨酸水平可能是乳腺癌的潜在生物标志物，化疗方案的选择不太可能对这些氨基酸水平产生显著影响。
